[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610567":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":39,"centralContacts":43,"locations":49,"responsibleParty":68,"collaborators":70,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":34,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":52,"whyStopped":34,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Medical College of Wisconsin","OTHER",[8,14,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Preeclampsia with Severe Features taking Mitoquinol Mesylate","EXPERIMENTAL","Patients allocated to this arm will be inpatients who have preeclampsia with severe features. They will receive 10mg of Mitoquinol Mesylate daily from enrollment until delivery.",[13],"Dietary Supplement: Mitoquinol Mesylate",{"label":15,"type":16,"description":17,"interventionNames":18},"Preeclampsia with Severe Features taking placebo","PLACEBO_COMPARATOR","Patients allocated to this arm will be inpatients who have preeclampsia with severe features. They will receive Placebo daily from enrollment until delivery.",[19],"Other: Placebo",{"label":21,"type":10,"description":22,"interventionNames":23},"Preeclampsia without Severe Features taking MitoQ","Patients allocated to this arm will be out-patients who have preeclampsia without severe features. They will receive 10mg of Mitoquinol Mesylate daily from enrollment until delivery.",[13],{"label":25,"type":16,"description":26,"interventionNames":27},"Preeclampsia without Severe Features taking placebo","Patients allocated to this arm will be out-patients who have preeclampsia without severe features. They will receive placebo daily from enrollment until delivery.",[19],[29,35],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DIETARY_SUPPLEMENT","Mitoquinol Mesylate","Patients randomized to the intervention will receive 10mg of Mitoquinol Mesylate daily from enrollment until delivery.",[9,21],null,{"type":6,"name":36,"description":37,"armGroupLabels":38,"otherNames":34},"Placebo","Patients randomized to the placebo groups will take 1 placebo capsule daily until delivery.",[15,25],[40],{"name":41,"affiliation":5,"role":42},"Jennifer J McIntosh, D.O.,","PRINCIPAL_INVESTIGATOR",[44],{"name":45,"role":46,"phone":47,"phoneExt":34,"email":48},"Jennifer McIntosh, D.O., M.S.","CONTACT","14148059019","jmcintosh@mcw.edu",[50],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Froedtert & the Medical College of Wisconsin","RECRUITING","Milwaukee","Wisconsin","53226","United States","US",{"type":59,"coordinates":60},"Point",[61,62],-87.90647,43.0389,{"lat":62,"lon":61},[65],{"name":66,"role":46,"phone":67,"phoneExt":34,"email":48},"Jennifer McIntosh","4148059019",{"type":42,"investigatorFullName":66,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":34,"oldOrganization":34},"Associate Professor",[71],{"name":72,"class":6},"Bill and Melinda Gates Foundation","100610567","mitoq-to-improve-vascular-funciton-in-preeclampsia-100610567",false,"NCT07229261","MitoQ to Improve Vascular Funciton in Preeclampsia","MitoQ (Mitoquinol Mesylate) to Ameliorate Vascular Function in Preeclampsia: a Novel Approach","MAVEN","Inclusion Criteria:\n\n* Inpatient Cohort\n\n  * pregnant patients with a clinical diagnosis of preeclampsia with severe features\n  * gestational age between 23+0 and 32+0 weeks' gestation\n  * singleton pregnancy\n  * age 18-50 years old\n  * No indication for immediate delivery (e.g. the patient and their physician team have planned expectant management of preeclampsia with severe features\n  * Able to consent and follow a 2-step commend\n  * English speaking\n* Outpatient Cohort\n\n  * Pregnant patients with a clinical diagnosis of preeclampsia without severe features\n  * gestational age between 23+0 and 34+0 weeks' gestation\n  * singleton pregnancy\n  * age 18-50 years old\n  * No indication for immediate delivery\n  * Planned outpatient management of preeclampsia\n  * Able to consent and follow a 2-step commend\n  * English speaking\n\nExclusion Criteria:\n\n* • Unable to stand from chair without physical assistance from another person (able to use assistive device).\n\n  * History of blood clots in the extremities or any condition in which compression of the thigh or transient ischemia is contraindicated (i.e., wounds in the leg).\n  * Chronic lasting symptoms (\\> 6 months) of severe COVID-19 (i.e., hospitalization)\n  * History of head trauma or concussion within the past 6 months\n  * Comorbid neurological disorder\n  * Peripheral vascular disease\n  * Diagnosed myocardial infarction or arrhythmia in the previous year\n  * Resting SBP ≥180 mmHg or DBP ≥ 100 mmHg\n  * Other significant medical condition likely to influence study or jeopardize safety as assessed by the Primary Investigator","FEMALE","18 Years","50 Years",{"count":85,"type":86},80,"ESTIMATED","INTERVENTIONAL",[89],"NA","Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. There is a lack of effective therapeutics for prevention or treatment. Our previous ex vivo work demonstrated that mitochondrial-antioxidants can reverse placental microvascular damage. Therefore, this study will evaluate whether MitoQ (Mitoquinol Mesylate, a mitochondrial-antioxidant) has the potential to restore vasodilation, improve placental function, and therefore promote pregnancy prolongation in patients with preeclampsia. This evaluation of clinical data, patient samples, and vascular function studies in patients with preeclampsia could translate into a viable therapeutic option.",[92,93],"Preeclampsia","Pregnancy",[95,96,97,98,99],"pregnancy","preeclampsia","MitoQ","Mitoquinone","Endothelial Function","2026-04-27",{"date":102,"type":103},"2026-05-01","ACTUAL",{"date":105,"type":103},"2026-03-18",{"date":107,"type":86},"2027-09-30",{"name":5,"class":6},1]